MX2015016726A - Preparado farmaceutico. - Google Patents

Preparado farmaceutico.

Info

Publication number
MX2015016726A
MX2015016726A MX2015016726A MX2015016726A MX2015016726A MX 2015016726 A MX2015016726 A MX 2015016726A MX 2015016726 A MX2015016726 A MX 2015016726A MX 2015016726 A MX2015016726 A MX 2015016726A MX 2015016726 A MX2015016726 A MX 2015016726A
Authority
MX
Mexico
Prior art keywords
solution
alpha
pharmaceutical preparation
daughter
selective binder
Prior art date
Application number
MX2015016726A
Other languages
English (en)
Other versions
MX366028B (es
Inventor
Janne Olsen Frenvik
Olav B Ryan
Alan Cuthbertson
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As filed Critical Bayer As
Publication of MX2015016726A publication Critical patent/MX2015016726A/es
Publication of MX366028B publication Critical patent/MX366028B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Extraction Or Liquid Replacement (AREA)

Abstract

Un método para generar una solución purificada de por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto una solución del complejo de radionúclido emisor alfa y por lo menos un núclido hijo que tiene por lo menos un ligante selectivo para los núclidos hijos y subsiguientemente separar la solución del ligante selectivo. También, un método para separar por lo menos un radionúclido hijo de una solución que comprende por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto la solución que tiene por lo menos un ligante selectivo para los núclidos hijos.
MX2015016726A 2013-06-05 2014-06-05 Un método para generar una solución purificada de por lo menos un isótopo de torio emisor alfa, un conjunto de elementos, un dispositivo de administración y un método para formar una solución inyectable. MX366028B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1310028.4A GB201310028D0 (en) 2013-06-05 2013-06-05 Pharmaceutical preparation
PCT/EP2014/061743 WO2014195423A1 (en) 2013-06-05 2014-06-05 Pharmaceutical preparation

Publications (2)

Publication Number Publication Date
MX2015016726A true MX2015016726A (es) 2016-06-28
MX366028B MX366028B (es) 2019-06-21

Family

ID=48805787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016726A MX366028B (es) 2013-06-05 2014-06-05 Un método para generar una solución purificada de por lo menos un isótopo de torio emisor alfa, un conjunto de elementos, un dispositivo de administración y un método para formar una solución inyectable.

Country Status (36)

Country Link
US (2) US20160114063A1 (es)
EP (1) EP3003401B1 (es)
JP (1) JP6580559B2 (es)
KR (1) KR102321763B1 (es)
CN (1) CN105592863B (es)
AP (1) AP2015008894A0 (es)
AU (1) AU2014276885B2 (es)
BR (1) BR112015030298A2 (es)
CA (1) CA2914278C (es)
CL (1) CL2015003554A1 (es)
CR (1) CR20150642A (es)
CU (1) CU24535B1 (es)
DK (1) DK3003401T3 (es)
DO (1) DOP2015000294A (es)
EA (1) EA201501174A1 (es)
ES (1) ES2782624T3 (es)
GB (1) GB201310028D0 (es)
HR (1) HRP20200456T1 (es)
IL (1) IL242704B (es)
LT (1) LT3003401T (es)
MA (1) MA38650B1 (es)
MX (1) MX366028B (es)
MY (1) MY180717A (es)
NI (1) NI201500173A (es)
PE (1) PE20160215A1 (es)
PH (1) PH12015502715A1 (es)
PL (1) PL3003401T3 (es)
PT (1) PT3003401T (es)
RS (1) RS60091B1 (es)
SA (1) SA515370233B1 (es)
SG (1) SG11201509856RA (es)
SI (1) SI3003401T1 (es)
TN (1) TN2015000527A1 (es)
UA (1) UA120352C2 (es)
WO (1) WO2014195423A1 (es)
ZA (1) ZA201600027B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
WO2022157094A2 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
NO347755B1 (en) * 2021-10-21 2024-03-18 Blue Wave Therapeutics Gmbh Peptide-coupled alginate gels comprising radionuclides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5749042A (en) * 1997-01-28 1998-05-05 Battelle Memorial Institute Bismuth generator method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
WO2010126979A1 (en) * 2009-04-29 2010-11-04 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation

Also Published As

Publication number Publication date
US20160114063A1 (en) 2016-04-28
EP3003401B1 (en) 2020-01-15
CL2015003554A1 (es) 2016-07-15
CU20150174A7 (es) 2016-06-29
WO2014195423A1 (en) 2014-12-11
MY180717A (en) 2020-12-07
IL242704B (en) 2020-06-30
JP2016521700A (ja) 2016-07-25
DOP2015000294A (es) 2016-03-15
KR102321763B1 (ko) 2021-11-05
JP6580559B2 (ja) 2019-09-25
BR112015030298A2 (pt) 2017-07-25
EP3003401A1 (en) 2016-04-13
CA2914278C (en) 2022-11-01
DK3003401T3 (da) 2020-04-06
LT3003401T (lt) 2020-06-25
UA120352C2 (uk) 2019-11-25
MA38650A1 (fr) 2018-03-30
EA201501174A1 (ru) 2016-10-31
ES2782624T3 (es) 2020-09-15
CA2914278A1 (en) 2014-12-11
CU24535B1 (es) 2021-07-02
PH12015502715B1 (en) 2016-03-28
SA515370233B1 (ar) 2019-05-30
PT3003401T (pt) 2020-04-09
PH12015502715A1 (en) 2016-03-28
PL3003401T3 (pl) 2020-07-27
CN105592863A (zh) 2016-05-18
HRP20200456T1 (hr) 2020-06-26
GB201310028D0 (en) 2013-07-17
KR20160030893A (ko) 2016-03-21
NI201500173A (es) 2016-01-06
MA38650B1 (fr) 2019-05-31
US20220023449A1 (en) 2022-01-27
AP2015008894A0 (en) 2015-12-31
MX366028B (es) 2019-06-21
TN2015000527A1 (en) 2017-04-06
NZ714737A (en) 2021-02-26
SG11201509856RA (en) 2015-12-30
RS60091B1 (sr) 2020-05-29
AU2014276885A1 (en) 2015-12-17
PE20160215A1 (es) 2016-05-22
SI3003401T1 (sl) 2020-06-30
CR20150642A (es) 2016-07-22
CN105592863B (zh) 2020-03-10
ZA201600027B (en) 2018-07-25
AU2014276885B2 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
HK1221060A1 (zh) 用於產生音頻文件的系統和方法
HK1249619A1 (zh) 用於查詢數據源的系統和方法
IL237525A (en) Method for labeling a prostate-specific membrane antigen with a radioactive isotope
PH12018501199A1 (en) Nicotine particle capsule
EP3160599A4 (en) Mobile processing system for hazardous and radioactive isotope removal
PL3289591T3 (pl) Układ do generowania radionuklidów i metoda wytwarzania radionuklidów
PH12015502715B1 (en) Pharmaceutical preparation
PL3257052T3 (pl) Układ do generowania radionuklidów
MX2016008369A (es) Composicion farmaceutica que incluye palonosetron.
FI20135630A (fi) Menetelmä kuparin ja jalometallien talteenottamiseksi
HK1201614A1 (en) Synchronization method for distributed transaction and system thereof
GB2545390B (en) Method and system for generating geophysical data
ZA201907263B (en) High length isotopes separation column and method for assembly
PH12016500847A1 (en) Multi-particulate drug delivery system
PL3049542T3 (pl) Sposób selektywnego odzyskiwania ołowiu i srebra
EP3335236A4 (en) RESEARCH OF TOLERANT LIBRARY TO ISOTOPES
PL3558418T3 (pl) Układ do infuzji środków radiofarmaceutycznych o krótkim czasie życia
SI3046112T1 (sl) Sistem za jemanje posod z jedrskim gorivom
GB201622269D0 (en) The recovery method of high-performance parallel file storage system after malfunction
EP3391956A4 (en) DEVICE AND METHOD FOR IMPAIR / PAIR SEPARATION AND IONIZATION OF PALLADIUM ISOTOPES
SG2013084512A (en) Method and system for collecting and parsing market data from various sources
AU2015904596A0 (en) Improved hydrometallurgical method for the removal of radionuclides from radioactive copper concentrates
GB201600413D0 (en) System and method for generating long token and subtoken for processing an interaction
AU2015901818A0 (en) Improved hydrometallurgical method for the removal of radionuclides from radioactive copper concentrates
GB201506284D0 (en) Cyclist alarm system (proximity)

Legal Events

Date Code Title Description
FG Grant or registration